This profile hasn't yet passed our validation checks
Submit your email to push it up the queue
Pentax Medical
Pentax Medical, a division of Hoya Corporation, is a leading provider of innovative medical imaging solutions, headquartered in Japan. Established in 1919, the company has a rich history of advancements in endoscopy and minimally invasive surgical technologies, serving healthcare professionals across the globe, particularly in Europe, Asia, and North America. Specialising in endoscopic equipment, Pentax Medical offers a range of products, including high-definition endoscopes and imaging systems that enhance diagnostic accuracy and patient outcomes. Their commitment to quality and innovation has positioned them as a trusted partner in the medical community, with notable achievements in developing user-friendly devices that prioritise patient safety and comfort. With a strong market presence, Pentax Medical continues to lead the way in transforming healthcare through cutting-edge technology.
DitchCarbon Score
How does Pentax Medical's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Pentax Medical's score of 41 is higher than 66% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Pentax Medical's reported carbon emissions
In 2025, Pentax Medical reported total carbon emissions of approximately 788,000 kg CO2e, with Scope 1 emissions at about 52,000 kg CO2e, Scope 2 emissions at around 29,000 kg CO2e, and a significant contribution from Scope 3 emissions, which totalled approximately 707,000 kg CO2e. This follows a similar trend in 2023, where total emissions were about 866,000 kg CO2e, with Scope 1 and Scope 2 emissions remaining consistent at approximately 52,000 kg CO2e and 29,000 kg CO2e, respectively, while Scope 3 emissions were around 785,000 kg CO2e. In 2022, the company reported total emissions of approximately 886,000 kg CO2e globally, with Scope 1 emissions at about 52,000 kg CO2e, Scope 2 emissions at around 29,000 kg CO2e, and Scope 3 emissions significantly higher at approximately 804,000 kg CO2e. Notably, in the UK, the same year saw total emissions of about 866,000 kg CO2e, with Scope 3 emissions reaching approximately 1,586,000 kg CO2e. Pentax Medical's emissions data is cascaded from its parent company, HOYA Corporation, which influences its sustainability initiatives and reporting. However, there are currently no specific reduction targets or climate pledges disclosed by Pentax Medical. The company continues to align its practices with industry standards, focusing on transparency in emissions reporting across all scopes.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | 2025 | |
|---|---|---|---|
| Scope 1 | 52,000 | 00,000 | 00,000 |
| Scope 2 | 29,000 | 00,000 | 00,000 |
| Scope 3 | 804,000 | 000,000 | 000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Pentax Medical is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
